1. Sun JC, Lanier LL. NK cell development, homeostasis and function: parallels with CD8+ T cells. Nature Reviews Immunology. 2011;11(10):645-57.
2. Obaldia MED, Bhandoola A. Transcriptional Regulation of Innate and Adaptive Lymphocyte Lineages. Annual Review of Immunology. 2015;33(1):607-42.
3. Chiossone L, Dumas P-Y, Vienne M, Vivier E. Natural killer cells and other innate lymphoid cells in cancer. Nature Reviews Immunology. 2018;18(11):671-88.
4. Martinet L, Smyth MJ. Balancing natural killer cell activation through paired receptors. Nature Reviews Immunology. 2015;15(4):243-54.
5. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nature Immunology. 2008;9(5):495-502.
6. Kumar S. Natural killer cell cytotoxicity and its regulation by inhibitory receptors. Immunology. 2018;154(3):383-93.
7. Vivier E, Nunès JA, Vély F. Natural Killer Cell Signaling Pathways. Science. 2004;306(5701):1517-9.
8. Cella M, Fujikawa K, Tassi I, Kim S, Latinis K, Nishi S, et al. Differential Requirements for Vav Proteins in DAP10- and ITAM-mediated NK Cell Cytotoxicity. Journal of Experimental Medicine. 2004;200(6):817-23.
9. Smyth MJ, Cretney E, Kelly JM, Westwood JA, Street SE, Yagita H, et al. Activation of NK cell cytotoxicity. Molecular immunology. 2005;42(4):501-10.
10. Konjević GM, Vuletić AM, Mirjačić Martinović KM, Larsen AK, Jurišić VB. The role of cytokines in the regulation of NK cells in the tumor environment. Cytokine. 2019;117:30- 40.
11. Herberman RB, Nunn ME, Holden HT, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. International Journal of Cancer. 1975;16(2):230-9.
12. Herberman RB, Nunn ME, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. I. Distribution of reactivity and specificity. International Journal of Cancer. 1975;16(2):216-29.
13. Smyth MJ, Hayakawa Y, Takeda K, Yagita H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nature Reviews Cancer. 2002;2(11):850-61.
14. Zitvogel L, Terme M, Borg C, Trinchieri G. Dendritic Cell-NK Cell Cross-Talk: Regulation and Physiopathology. In: Compans RW, Cooper MD, Honjo T, Koprowski H, Melchers F, Oldstone MBA, et al., editors. Immunobiology of Natural Killer Cell Receptors. Berlin, Heidelberg: Springer Berlin Heidelberg; 2006. p. 157-74.
15. Hayakawa Y, Smyth MJ. CD27 Dissects Mature NK Cells into Two Subsets with Distinct Responsiveness and Migratory Capacity. The Journal of Immunology. 2006;176(3):1517-24.
16. Freud AG, Yu J, Caligiuri MA. Human natural killer cell development in secondary lymphoid tissues. Semin Immunol. 2014;26(2):132-7.
17. Hayakawa Y, Huntington ND, Nutt SL, Smyth MJ. Functional subsets of mouse natural killer cells. Immunological Reviews. 2006;214(1):47-55.
18. Silva A, Andrews DM, Brooks AG, Smyth MJ, Hayakawa Y. Application of CD27 as a marker for distinguishing human NK cell subsets. International Immunology. 2008;20(4):625-30.
19. Freud AG, Mundy-Bosse BL, Yu J, Caligiuri MA. The Broad Spectrum of Human Natural Killer Cell Diversity. Immunity. 2017;47(5):820-33.
20. Huntington ND, Vosshenrich CAJ, Di Santo JP. Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nature Reviews Immunology. 2007;7(9):703-14.
21. Sun JC. Transcriptional Control of NK Cells. In: Vivier E, Di Santo J, Moretta A, editors. Natural Killer Cells. Cham: Springer International Publishing; 2016. p. 1-36.
22. Seillet C, Belz GT, Huntington ND. Development, Homeostasis, and Heterogeneity of NK Cells and ILC1. In: Vivier E, Di Santo J, Moretta A, editors. Natural Killer Cells. Cham: Springer International Publishing; 2016. p. 37-61.
23. Townsend MJ, Weinmann AS, Matsuda JL, Salomon R, Farnham PJ, Biron CA, et al. T-bet Regulates the Terminal Maturation and Homeostasis of NK and Vα14i NKT Cells. Immunity. 2004;20(4):477-94.
24. Gordon Scott M, Chaix J, Rupp Levi J, Wu J, Madera S, Sun Joseph C, et al. The Transcription Factors T-bet and Eomes Control Key Checkpoints of Natural Killer Cell Maturation. Immunity. 2012;36(1):55-67.
25. Daussy C, Faure F, Mayol K, Viel S, Gasteiger G, Charrier E, et al. T-bet and Eomes instruct the development of two distinct natural killer cell lineages in the liver and in the bone marrow. Journal of Experimental Medicine. 2014;211(3):563-77.
26. Takahashi K, Yamanaka S. A decade of transcription factor-mediated reprogramming to pluripotency. Nature Reviews Molecular Cell Biology. 2016;17(3):183-93.
27. 国立がん研究センター.
28. 厚生労働省 令和元年人口動態統計.
29. Sanmamed MF, Chen L. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell. 2018;175(2):313-26.
30. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nature Medicine. 2013;19(11):1423-37.
31. Dunn GP, Old LJ, Schreiber RD. The Immunobiology of Cancer Immunosurveillance and Immunoediting. Immunity. 2004;21(2):137-48.
32. Schreiber RD, Old LJ, Smyth MJ. Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion. Science. 2011;331(6024):1565-70.
33. Delahaye NF, Rusakiewicz S, Martins I, Ménard C, Roux S, Lyonnet L, et al. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nature Medicine. 2011;17(6):700-7.
34. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Che X, Iwashige H, et al. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer. 2000;88(3):577-83.
35. Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A, Saez MA, Vallejo C, et al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer. 1997;79(12):2320-8.
36. Donskov F, Maase Hvd. Impact of Immune Parameters on Long-Term Survival in Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 2006;24(13):1997-2005.
37. Gannon PO, Poisson AO, Delvoye N, Lapointe R, Mes-Masson A-M, Saad F. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. Journal of Immunological Methods. 2009;348(1):9-17.
38. Pasero C, Gravis G, Guerin M, Granjeaud S, Thomassin-Piana J, Rocchi P, et al. Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity. Cancer Research. 2016;76(8):2153-65.
39. Ménard C, Blay J-Y, Borg C, Michiels S, Ghiringhelli F, Robert C, et al. Natural Killer Cell IFN-γ Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumor–Bearing Patients. Cancer Research. 2009;69(8):3563-9.
40. Semeraro M, Rusakiewicz S, Zitvogel L, Kroemer G. Natural killer cell mediated immunosurveillance of pediatric neuroblastoma. OncoImmunology. 2015;4(11):e1042202.
41. Street SE, Cretney E, Smyth MJ. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood. 2001;97(1):192-7.
42. Smyth MJ, Thia KY, Cretney E, Kelly JM, Snook MB, Forbes CA, et al. Perforin is a major contributor to NK cell control of tumor metastasis. J Immunol. 1999;162(11):6658- 62.
43. Takeda K, Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, Kakuta S, et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nature Medicine. 2001;7(1):94-100.
44. Shalapour S, Karin M. Pas de Deux: Control of Anti-tumor Immunity by Cancer- Associated Inflammation. Immunity. 2019;51(1):15-26.
45. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436-44.
46. Grivennikov SI, Karin M. Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Annals of the Rheumatic Diseases. 2011;70(Suppl 1):i104- i8.
47. Suganuma M, Okabe S, Kurusu M, Iida N, Ohshima S, Saeki Y, et al. Discrete roles of cytokines, TNF-alpha, IL-1, IL-6 in tumor promotion and cell transformation. Int J Oncol. 2002;20(1):131-6.
48. Zhong Z, Wen Z, Darnell J. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science. 1994;264(5155):95-8.
49. HEINRICH PC, BEHRMANN I, MÜLLER-NEWEN G, SCHAPER F, GRAEVE L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway1. Biochemical Journal. 1998;334(2):297-314.
50. Taga T, Kishimoto T. gp130 AND THE INTERLEUKIN-6 FAMILY OF CYTOKINES. Annual Review of Immunology. 1997;15(1):797-819.
51. Liu Y, Huang J, Li W, Chen Y, Liu X, Wang J. Meta-analysis of STAT3 and phospho- STAT3 expression and survival of patients with breast cancer. Oncotarget. 2018;9(16).
52. Ara T, Song L, Shimada H, Keshelava N, Russell HV, Metelitsa LS, et al. Interleukin-6 in the Bone Marrow Microenvironment Promotes the Growth and Survival of Neuroblastoma Cells. Cancer Research. 2009;69(1):329-37.
53. Shain KH, Yarde DN, Meads MB, Huang M, Jove R, Hazlehurst LA, et al. β1 Integrin Adhesion Enhances IL-6–Mediated STAT3 Signaling in Myeloma Cells: Implications for Microenvironment Influence on Tumor Survival and Proliferation. Cancer Research. 2009;69(3):1009-15.
54. Grivennikov S, Karin E, Terzic J, Mucida D, Yu G-Y, Vallabhapurapu S, et al. IL-6 and Stat3 Are Required for Survival of Intestinal Epithelial Cells and Development of Colitis- Associated Cancer. Cancer Cell. 2009;15(2):103-13.
55. Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H, Yu H. Stat3 mediates myeloid cell–dependent tumor angiogenesis in mice. The Journal of Clinical Investigation. 2008;118(10):3367-77.
56. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proceedings of the National Academy of Sciences. 1994;91(9):4082-5.
57. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nature Reviews Cancer. 2004;4(4):314-22.
58. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, et al. Identification of a Primary Target of Thalidomide Teratogenicity. Science. 2010;327(5971):1345-50.
59. Ito T, Ando H, Handa H. Teratogenic effects of thalidomide: molecular mechanisms. Cellular and Molecular Life Sciences. 2011;68(9):1569-79.
60. Asatsuma-Okumura T, Ito T, Handa H. Molecular Mechanisms of the Teratogenic Effects of Thalidomide. Pharmaceuticals. 2020;13(5):95.
61. Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS, et al. The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins. Science. 2014;343(6168):305-9.
62. Matyskiela ME, Lu G, Ito T, Pagarigan B, Lu C-C, Miller K, et al. A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase. Nature. 2016;535(7611):252- 7.
63. Zhu YX, Braggio E, Shi C-X, Bruins LA, Schmidt JE, Van Wier S, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood. 2011;118(18):4771-9.
64. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol. 1999;163(1):380-6.
65. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai Y-T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98(1):210-6.
66. Galustian C, Meyer B, Labarthe M-C, Dredge K, Klaschka D, Henry J, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunology, Immunotherapy. 2009;58(7):1033-45.
67. Cortes M, Wong E, Koipally J, Georgopoulos K. Control of lymphocyte development by the Ikaros gene family. Current Opinion in Immunology. 1999;11(2):167-71.
68. Holmes ML, Huntington ND, Thong RP, Brady J, Hayakawa Y, Andoniou CE, et al. Peripheral natural killer cell maturation depends on the transcription factor Aiolos. The EMBO Journal. 2014;33(22):2721-34.
69. Fionda C, Abruzzese MP, Zingoni A, Cecere F, Vulpis E, Peruzzi G, et al. The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma. Oncotarget. 2015;6(27).
70. Haslett PAJ, Corral LG, Albert M, Kaplan G. Thalidomide Costimulates Primary Human T Lymphocytes, Preferentially Inducing Proliferation, Cytokine Production, and Cytotoxic Responses in the CD8+ Subset. Journal of Experimental Medicine. 1998;187(11):1885-92.
71. LeBlanc R, Hideshima T, Catley LP, Shringarpure R, Burger R, Mitsiades N, et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood. 2004;103(5):1787-90.
72. Lazarevic V, Glimcher LH, Lord GM. T-bet: a bridge between innate and adaptive immunity. Nature Reviews Immunology. 2013;13(11):777-89.
73. Chamoto K, Takeshima T, Kosaka A, Tsuji T, Matsuzaki J, Togashi Y, et al. NKT cells act as regulatory cells rather than killer cells during activation of NK cell-mediated cytotoxicity by α-galactosylceramide in vivo. Immunology Letters. 2004;95(1):5-11.
74. Taylor A, Harker JA, Chanthong K, Stevenson PG, Zuniga EI, Rudd CE. Glycogen Synthase Kinase 3 Inactivation Drives T-bet-Mediated Downregulation of Co-receptor PD-1 to Enhance CD8+ Cytolytic T Cell Responses. Immunity. 2016;44(2):274-86.
75. Parameswaran R, Ramakrishnan P, Moreton SA, Xia Z, Hou Y, Lee DA, et al. Repression of GSK3 restores NK cell cytotoxicity in AML patients. Nature Communications. 2016;7(1):11154.
76. Gribben JG, Fowler N, Morschhauser F. Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma. Journal of Clinical Oncology. 2015;33(25):2803-11.
77. Gandhi AK, Kang J, Havens CG, Conklin T, Ning Y, Wu L, et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN. British Journal of Haematology. 2014;164(6):811-21.
78. Takeda K, Nakayama M, Sakaki M, Hayakawa Y, Imawari M, Ogasawara K, et al. IFN-γ production by lung NK cells is critical for the natural resistance to pulmonary metastasis of B16 melanoma in mice. Journal of Leukocyte Biology. 2011;90(4):777-85.
79. Lagrue K, Carisey A, Morgan DJ, Chopra R, Davis DM. Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds. Blood. 2015;126(1):50-60.
80. Collins A, Rothman N, Liu K, Reiner SL. Eomesodermin and T-bet mark developmentally distinct human natural killer cells. JCI Insight. 2017;2(5).
81. van Helden MJ, Goossens S, Daussy C, Mathieu A-L, Faure F, Marçais A, et al. Terminal NK cell maturation is controlled by concerted actions of T-bet and Zeb2 and is essential for melanoma rejection. Journal of Experimental Medicine. 2015;212(12):2015-25.
82. Werneck MBF, Lugo-Villarino G, Hwang ES, Cantor H, Glimcher LH. T-Bet Plays a Key Role in NK-Mediated Control of Melanoma Metastatic Disease. The Journal of Immunology. 2008;180(12):8004-10.
83. Cichocki F, Valamehr B, Bjordahl R, Zhang B, Rezner B, Rogers P, et al. GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity. Cancer Research. 2017;77(20):5664-75.
84. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A Novel Transcription Factor, T-bet, Directs Th1 Lineage Commitment. Cell. 2000;100(6):655-69.
85. Sullivan BM, Juedes A, Szabo SJ, von Herrath M, Glimcher LH. Antigen-driven effector CD8 T cell function regulated by T-bet. Proceedings of the National Academy of Sciences. 2003;100(26):15818-23.
86. Spits H, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, et al. Innate lymphoid cells — a proposal for uniform nomenclature. Nature Reviews Immunology. 2013;13(2):145-9.
87. Klose Christoph SN, Blatz K, d’Hargues Y, Hernandez Pedro P, Kofoed-Nielsen M, Ripka Juliane F, et al. The Transcription Factor T-bet Is Induced by IL-15 and Thymic Agonist Selection and Controls CD8αα+ Intraepithelial Lymphocyte Development. Immunity. 2014;41(2):230-43.
88. Malaisé M, Rovira J, Renner P, Eggenhofer E, Sabet-Baktach M, Lantow M, et al. KLRG1<sup>+</sup> NK Cells Protect T-bet–Deficient Mice from Pulmonary Metastatic Colorectal Carcinoma. The Journal of Immunology. 2014;192(4):1954-61.
89. Sehgal K, Das R, Zhang L, Verma R, Deng Y, Kocoglu M, et al. Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets. Blood. 2015;125(26):4042-51.
90. Lu L, Payvandi F, Wu L, Zhang L-H, Hariri RJ, Man H-W, et al. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvascular Research. 2009;77(2):78-86.
91. Ishdorj G, Johnston JB, Gibson SB. Inhibition of Constitutive Activation of STAT3 by Curcurbitacin-I (JSI-124) Sensitized Human B-Leukemia Cells to Apoptosis. Molecular Cancer Therapeutics. 2010;9(12):3302-14.
92. Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res. 2003;63(6):1270-9.
93. Kortylewski M, Yu H. Role of Stat3 in suppressing anti-tumor immunity. Current Opinion in Immunology. 2008;20(2):228-33.
94. Wu C-J, Sundararajan V, Sheu B-C, Huang RY-J, Wei L-H. Activation of STAT3 and STAT5 Signaling in Epithelial Ovarian Cancer Progression: Mechanism and Therapeutic Opportunity. Cancers. 2020;12(1):24.
95. Rodrigues T, Reker D, Schneider P, Schneider G. Counting on natural products for drug design. Nature Chemistry. 2016;8(6):531-41.
96. Orlikova B, Legrand N, Panning J, Dicato M, Diederich M, editors. Anti-Inflammatory and Anticancer Drugs from Nature2014; Berlin, Heidelberg: Springer Berlin Heidelberg.
97. Johnson DE, O'Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nature Reviews Clinical Oncology. 2018;15(4):234-48.
98. Rokavec M, Öner MG, Li H, Jackstadt R, Jiang L, Lodygin D, et al. IL- 6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. The Journal of Clinical Investigation. 2014;124(4):1853-67.
99. Chai EZP, Shanmugam MK, Arfuso F, Dharmarajan A, Wang C, Kumar AP, et al. Targeting transcription factor STAT3 for cancer prevention and therapy. Pharmacology & Therapeutics. 2016;162:86-97.
100. Browning L, Patel MR, Horvath EB, Tawara K, Jorcyk CL. IL-6 and ovarian cancer: inflammatory cytokines in promotion of metastasis. Cancer Manag Res. 2018;10:6685-93.
101. Gao Y, Snyder SA, Smith JN, Chen YC. Anticancer properties of baicalein: a review. Medicinal Chemistry Research. 2016;25(8):1515-23.
102. Ke M, Zhang Z, Xu B, Zhao S, Ding Y, Wu X, et al. Baicalein and baicalin promote antitumor immunity by suppressing PD-L1 expression in hepatocellular carcinoma cells. International Immunopharmacology. 2019;75:105824.
103. Avalle L, Pensa S, Regis G, Novelli F, Poli V. STAT1 and STAT3 in tumorigenesis. JAK-STAT. 2012;1(2):65-72.
104. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nature Reviews Cancer. 2009;9(11):798-809.
105. Eswaran D, Suyun H. STAT3 as a Central Regulator of Tumor Metastases. Current Molecular Medicine. 2009;9(5):626-33.
106. Huang S. Regulation of Metastases by Signal Transducer and Activator of Transcription 3 Signaling Pathway: Clinical Implications. Clinical Cancer Research. 2007;13(5):1362-6.
107. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nature Medicine. 2005;11(12):1314-21.
108. Wu J, Gao F-x, Wang C, Qin M, Han F, Xu T, et al. IL-6 and IL-8 secreted by tumour cells impair the function of NK cells via the STAT3 pathway in oesophageal squamous cell carcinoma. Journal of Experimental & Clinical Cancer Research. 2019;38(1):321.
109. Fujiwara Y, Sun Y, Torphy RJ, He J, Yanaga K, Edil BH, et al. Pomalidomide Inhibits PD-L1 Induction to Promote Antitumor Immunity. Cancer Research. 2018;78(23):6655-65.
110. Kawamata A, Ito D, Odani T, Isobe T, Iwase M, Hatori M, et al. Thalidomide suppresses melanoma growth by activating natural killer cells in mice. Oncol Rep. 2006;16(6):1231-6.
111. Gotthardt D, Putz EM, Straka E, Kudweis P, Biaggio M, Poli V, et al. Loss of STAT3 in murine NK cells enhances NK cell–dependent tumor surveillance. Blood. 2014;124(15):2370-9.
112. Cacalano NA. Regulation of Natural Killer Cell Function by STAT3. Frontiers in Immunology. 2016;7(128).